1Stegg PS, Bevilaena G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential[J]. J Natl Cancer Inst, 1988, 80(3):200-204.
2Gilles AM, Presecan E, Vonica A, et al. Nucleoside diphosphate kinase from human erythrocytes[J]. Biol Chem,1991,266:8784-8789.
3Otsuki Y, Tanaka M, Yoshii S, et al. Tumor metastasis suppressor nm23H1 reglates Racl GTPase by interaction with Tiaml [J]. Proc Natl Acad Sci USA, 2001,98(8):4385.
4Liotta LA, Steeg PS. Clues to the function of nm23 and Awd proteins in development, signal transtuction and tumor metastasis provided by studies of dictyostelium discoideum[J]. J Natl Cancer Inst, 1990,82:1170-1172.
5Daberna S, Larou M, Masse K, et al. Organization and expression of mouse nm23H1 gene comparison with nm23H2 gene expression[J]. Gene, 1999,236:221.
6Fan Z, Beresford PJ, Oh DY, et al. Tumor, suppresser nm23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis,and the nucleoseme assembly protein SET is its inhibitor[J]. Cell, 2003,112(5): 659.
7Lai WW, Wu MH, Yan JJ, et al. Immunohistochemical analysis of nm23H1 in stage I non-small cell lung cancer useful marker in prediction of metastasis[J]. Ann Thorac Surg, 1996,62:1500-1505.
8Lau DH, Lu D, Hammond WG, et al. Loss of nm23 and Alu DNA in human lung cancer propagated in nude mice[J]. Cancer Lett, 1995,97:163-169.
8Fujii K, Yasui W, Shimamoto F, et al. Immunohistochemical analysis of nm23 gene product in human gallbladder carcinomas [ J]. Virchows Arch, 1995; 426 (2): 355 - 359.
9Shi Y, Parhar Rs, Zou M, et al. Differential nm23 gene expression at the fetal-maternal interface [ J ]. Br J Cancer, 1994; 70:440 - 448.
10Kalekou H, Miliaras D. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma [J]. J Gastroenterol Hepatol, 2004; 19(7): 812-818.
7Zheng LZ, Wang LW, Ajani J, et al. Molecular basis of gastric cancer development and progression. Gastric Cancer, 2004,7:61-77.
8Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular mark- ers. CA Cancer J Clin, 2003,53:44-55.
